Fig. 6

GOT1 expression in different types of cancer and the involvement in overall survival rate. a GOT1 mRNA expression in normal control tissue (n = 56) and primary lung adenocarcinoma tissue (n = 56). Wilcoxon test was performed. b GOT1 mRNA expression in normal control tissue (n = 26), primary lung adenocarcinoma tissue (n = 26) and metastatic adenocarcinoma (n = 26). All 26 subjects contributed with normal, primary and metastatic samples. Wilcoxon test was performed. c GOT1 mRNA expression in normal control samples (n = 53) and early Non-small cell lung carcinoma samples (NSCLC) (n = 92) analyzed from the GEO:GSE database. Unpaired student’s t-test was performed. d GOT1 mRNA expression in primary melanoma (n = 30) and metastatic melanoma (n = 53) analyzed from the GEO:GSE database. Unpaired student’s t-test was performed. e The diversity of expression of GOT1 in different types of cancers analyzed by the GEPIA web tool. DLBC: lymphoid neoplasm diffuse large B-cell lymphoma; PAAD: pancreatic adenocarcinoma; THYM: thymoma; GBM: glioblastoma multiforme; KIRC: kidney renal clear cell carcinoma; LAML: acute myeloid leukemia; LGG: brain lower grade glioma; TGCT: testicular germ cell cancers; f-h The relationship of GOT1 mRNA expression and overall survival rate analyzed by the GEPIA web tool, in f, thyroid carcinoma, g, in breast invasive carcinoma and h, in lung adenocarcinoma. *** p < 0.001; ** p < 0.01; * p < 0.05; NS: not significant